Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(1.24)
# 3,450
Out of 4,843 analysts
111
Total ratings
32.29%
Success rate
-12.83%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.35 | +623.40% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $123.02 | +30.06% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $129.79 | +69.50% | 21 | May 2, 2025 | |
| CRVO CervoMed | Maintains: Buy | $12 → $21 | $7.22 | +190.86% | 5 | Mar 18, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $8.55 | +192.40% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $2.74 | +337.96% | 5 | Mar 13, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $23 → $15 | $4.16 | +260.58% | 3 | Feb 28, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $9 → $8 | $6.46 | +23.84% | 5 | Feb 12, 2025 | |
| CYBN Cybin | Maintains: Buy | $86 → $73 | $7.96 | +817.09% | 7 | Feb 12, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $1.18 | +6,679.66% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.04 | +132.56% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $2.31 | +376.19% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.19 | +2,501.88% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $7.26 | +92.84% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $9.55 | +109.53% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.57 | +52.99% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $14.81 | +912.83% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.78 | - | 2 | Jan 31, 2017 |
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.35
Upside: +623.40%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $123.02
Upside: +30.06%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $129.79
Upside: +69.50%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $12 → $21
Current: $7.22
Upside: +190.86%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $8.55
Upside: +192.40%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $2.74
Upside: +337.96%
COMPASS Pathways
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $15
Current: $4.16
Upside: +260.58%
Sage Therapeutics
Feb 12, 2025
Maintains: Hold
Price Target: $9 → $8
Current: $6.46
Upside: +23.84%
Cybin
Feb 12, 2025
Maintains: Buy
Price Target: $86 → $73
Current: $7.96
Upside: +817.09%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.18
Upside: +6,679.66%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.04
Upside: +132.56%
Nov 18, 2024
Maintains: Buy
Price Target: $11
Current: $2.31
Upside: +376.19%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.19
Upside: +2,501.88%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $7.26
Upside: +92.84%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $9.55
Upside: +109.53%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.57
Upside: +52.99%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $14.81
Upside: +912.83%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.78
Upside: -